Bristol Myers Squibb II-ON RFP: Immuno-Oncology and Cell Therapy

Bristol Myers Squibb seeks proposals on topics designed to address questions developed by its Immuno-Oncology and Cell Therapy (IOCT) Thematic Research Center.

Areas of interest:

• Approaches to normalize the tumor vasculature to improve cell therapy/T cell engagers/NK cell engager therapies
• Novel technology which can support cell therapy target identification for solid tumors
• Targeting T cell metabolism pathways to improve T cell fitness for cell therapy in vivo

RFP guidelines:

• Total budgets (direct + indirect) generally should not exceed USD $250k-350k/ 12 month funding period
• Please utilize II-ON Proposal Template for your submission (see Related Documents)
• Collaborating with multiple institutions encouraged

Timeline for submission: 

• Proposals due February 5, 2021 to techventures@columbia.edu
• BMS Review process February 12 – March 5, 2021
• Communication of decisions week of March 12, 2021